据印度代购了解，特罗凯耐药后不少病友不想再次穿刺活检，不想再次行基因检测，不想加化疗，不想做放疗，就结合其他的靶向药停止治疗，特罗凯耐药后结合XL184治疗有没有用?

According to Daigou India, after tarceva resistance, many patients do not want to do puncture biopsy again, do not want to undergo genetic testing again, do not want to add chemotherapy, do not want to do radiotherapy, they combined with other targeted drugs to stop the treatment, tarceva resistance combined with XL184 is there any use?

据印度代购了解，此前有过一项研讨，是64名对特罗凯耐药的晚期肺癌患者承受XL184结合特罗凯治疗，有效率是8.2%。随后，该研讨小组又依照上述小范围临床实验探究出来的最佳剂量停止了拓展实验，结果最初入组的14名患者，有效率只要6.7%，实验被迫提早完毕。

据印度代购了解，事实上，后来的研讨提示，对MET抑止剂敏感的或许是那些MET基因14号外显子腾跃突变的病友，对XL184敏感的或许是那些RET基因交融突变的病友。而这两类病友所占的比例是不高的，未经检测而自觉结合INC280或XL184，绝大多数病友是无效的。

据印度代购了解，所以倡议患者在特罗凯耐药后，还是重新靶向然后在选择是治疗计划，不要自觉的停止。

According to daigou India, patients who are resistant to tarceva are advised to re-target and then choose a treatment plan without consciously stopping.